Get the Stockscreener App
0.2603
0.12%
0.0004
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Prophase Labs Inc stock is traded at $0.2603, with a volume of 267.61K.
It is up +0.12% in the last 24 hours and down -63.62% over the past month.
ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.
See More
Previous Close:
$0.2599
Open:
$0.26
24h Volume:
267.61K
Relative Volume:
0.45
Market Cap:
$6.20M
Revenue:
$62.71M
Net Income/Loss:
$-10.48M
P/E Ratio:
-0.4132
EPS:
-0.63
Net Cash Flow:
$-13.77M
1W Performance:
-1.18%
1M Performance:
-63.62%
6M Performance:
-89.91%
1Y Performance:
-95.00%
1-Day Range:
$0.25
$0.2753
1-Week Range:
$0.2179
$0.2941
52-Week Range:
$0.2179
$7.48
Prophase Labs Inc Stock (PRPH) Company Profile
Name
Prophase Labs Inc
Sector
Industry
Phone
(215) 345-0919
Address
711 STEWART AVE, SUITE 200, NEW YORK, PA
Compare PRPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRPH
Prophase Labs Inc
|
0.2603 | 6.20M | 62.71M | -10.48M | -13.77M | -0.63 |
|
TMO
Thermo Fisher Scientific Inc
|
569.18 | 219.06B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
206.94 | 151.02B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
145.24 | 42.12B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
458.15 | 37.71B | 3.84B | 866.24M | 792.60M | 10.37 |
|
IQV
Iqvia Holdings Inc
|
207.25 | 36.97B | 15.32B | 1.41B | 1.96B | 7.62 |
Prophase Labs Inc Stock (PRPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-21 | Initiated | H.C. Wainwright | Buy |
| Oct-13-21 | Downgrade | Dawson James | Buy → Neutral |
| Jan-20-21 | Initiated | Dawson James | Buy |
Prophase Labs Inc Stock (PRPH) Latest News
ProPhase Labs Inc [PRPH] moved up 1.41: Why It’s Important - The DBT News
PRPH’s Q2 earnings predictions: What the experts say - US Post News
ProPhase Labs Enters into Common Stock Purchase Agreement with Equity Line Investor - Defense World
ProPhase Labs (NASDAQ:PRPH) Coverage Initiated by Analysts at StockNews.com - Defense World
ProPhase Labs stock hits 52-week low at $0.41 amid sharp decline - MSN
ProPhase Labs, Inc. (PRPH) Reports Q3 Loss, Tops Revenue Estimates - MSN
StockNews.com Initiates Coverage on ProPhase Labs (NASDAQ:PRPH) - Defense World
ProPhase Labs Announces Closing of $23.6 Million Sale of - GlobeNewswire
ProPhase Labs Stock Hits 52-Week Low at $0.56 Amid Market Struggles - MSN
An undisclosed buyer acquired Pharmaloz Manufacturing Inc. and Pharmaloz Real Estate Holdings, Inc. from ProPhase Labs, Inc. for approximately $23.6 million. - Marketscreener.com
ProPhase Labs Stock Hits 52-Week Low at $0.56 Amid Market Struggles By Investing.com - Investing.com South Africa
ProPhase Labs Closes $23.6 Million Sale of Pharmaloz Manufacturing to Houston-Based Private Equity Firm - citybiz
ProPhase Labs Sells Manufacturing Units for $23.6M, Eliminates $20M in Debt in Strategic Sale - StockTitan
PRPH (ProPhase Labs) 3-Year Book Growth Rate : 44.30% (As of Sep. 2024) - GuruFocus.com
PRPH (ProPhase Labs) Debt-to-EBITDA : -1.36 (As of Sep. 2024) - GuruFocus.com
ProPhase Labs stock hits 52-week low at $0.61 amid sharp decline - Investing.com Canada
ProPhase Labs Receives Notice from NASDAQ Regarding Minimum Bid Price Requirement On December 26, 2024, ProPhase Labs, Inc. (NASDAQ: PRPH) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC, indicating that t - Defense World
ProPhase Labs faces potential Nasdaq delisting over share price By Investing.com - Investing.com Nigeria
ProPhase Labs faces potential Nasdaq delisting over share price - Investing.com
HighTower Advisors LLC Boosts Stock Position in ProPhase Labs, Inc. (NASDAQ:PRPH) - Defense World
ProPhase Labs stock hits 52-week low at $0.64 amid sharp decline - Investing.com Australia
ProPhase Labs stock hits 52-week low at $0.64 amid sharp decline By Investing.com - Investing.com South Africa
ProPhase Labs stock hits 52-week low at $0.66 amid sharp decline By Investing.com - Investing.com South Africa
ProPhase Labs stock hits 52-week low at $0.66 amid sharp decline - Investing.com
ProPhase Labs secures private equity backing, nears lozenge deal, and plans cost-cutting measures - MSN
ProPhase Labs Secures Global Private Equity Backing, Nears Major Lozenge Deal, Adds Seasoned Industry Expert, and Plans Significant Cost-Cutting Measures - The Manila Times
ProPhase Labs Secures Global Private Equity Backing, Nears - GlobeNewswire
ProPhase Labs Secures Game-Changing Financing Deal, Eyes Major Asian Market Expansion - StockTitan
PRPH (ProPhase Labs) 5-Day RSI : 18.93 (As of Dec. 05, 2024) - GuruFocus.com
ProPhase Labs Launches Genetic Testing Subsidiary with Advanced Technology - Precedence Research
PRPH (ProPhase Labs) Growth Rank : 9 (As of Nov. 26, 2024) - GuruFocus.com
ProPhase Labs, Inc. (NASDAQ:PRPH) Q3 2024 Earnings Call Transcript - MSN
ProPhase Labs plummets 21%, prices $3M equity offering - MSN
ProPhase Labs 4.17M share Spot Secondary priced at $.72 - MSN
ProPhase Labs Inc (PRPH) Q3 2024 Earnings Call Highlights: Strat - GuruFocus.com
ProPhase Labs Inc (PRPH) Q3 2024 Earnings Call Highlights: Strategic Launches and Financial ... - Yahoo Finance
ProPhase Labs Inc (PRPH) Q3 2024 Earnings Call Highlights: Strategic Launches and Financial ... By GuruFocus - Investing.com Canada
Diamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH) - EIN News
Earnings call: Prophase Labs' Q3 2024 reveals strategic growth initiatives By Investing.com - Investing.com Australia
Arcutis Biotherapeutics (NASDAQ:ARQT) versus ProPhase Labs (NASDAQ:PRPH) Critical Survey - Defense World
ProPhase Labs: Strategic Moves for Future Growth - TipRanks
ProPhase Labs Announces Financial Results for the Three Months Ended September 30, 2024 - The Manila Times
Q3 2024 Prophase Labs Inc Earnings Call Transcript - GuruFocus.com
ProPhase Labs Announces Closing of Public Offering of Common Stock - GlobeNewswire
Prophase Labs Inc Stock (PRPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.57%
1.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):